Compare RYAN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | GRFS |
|---|---|---|
| Founded | 2010 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.9B |
| IPO Year | 2021 | 2006 |
| Metric | RYAN | GRFS |
|---|---|---|
| Price | $58.27 | $8.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 1 |
| Target Price | ★ $67.50 | $10.30 |
| AVG Volume (30 Days) | ★ 1.5M | 751.4K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | 0.83% | ★ 1.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | $2,905,944,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $27.58 | $5.31 |
| Revenue Next Year | $16.69 | $6.02 |
| P/E Ratio | $217.26 | ★ $16.99 |
| Revenue Growth | ★ 24.99 | 7.31 |
| 52 Week Low | $50.08 | $6.19 |
| 52 Week High | $77.16 | $11.14 |
| Indicator | RYAN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 49.11 |
| Support Level | $55.54 | $8.33 |
| Resistance Level | $57.84 | $8.64 |
| Average True Range (ATR) | 1.40 | 0.21 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 81.45 | 82.64 |
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.